About Synaffix
Synaffix is a company based in Nijmegen (Netherlands) founded in 2010 was acquired by Lonza in June 2023. It operates as a Licensing Model. Synaffix offers products and services including GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads. Synaffix operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Regeneron Pharmaceuticals, Erasca and Revolution Medicines, among others.
- Headquarter Nijmegen, Netherlands
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Synaffix B.V.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Synaffix
Synaffix offers a comprehensive portfolio of products and services, including GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for antibody-drug conjugate development is provided.
Spacer technology for enhanced ADC efficacy is offered.
Linker-payloads for targeted cancer therapies are developed.
Unlock access to complete
Funding Insights of Synaffix
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2014 | Amount | Series A - Synaffix | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Synaffix
Synaffix has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lonza, BOM and BioGeneration Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science focused VC firm investing in startups in Europe
|
Founded Year | Domain | Location | |
|
Investments are directed by BOM toward early and growth-stage firms.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Synaffix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Synaffix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Synaffix Comparisons
Competitors of Synaffix
Synaffix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Regeneron Pharmaceuticals, Erasca and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Synaffix
Frequently Asked Questions about Synaffix
When was Synaffix founded?
Synaffix was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Where is Synaffix located?
Synaffix is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
What does Synaffix do?
Synaffix is engaged in the development of clinical-stage platform technologies for antibody-drug conjugates (ADCs) and bispecifics, primarily targeting cancer therapeutics. The companys proprietary solutions, including GlycoConnect, HydraSpace, and toxSYN linker-payloads, are designed to enable best-in-class targeted therapies. Operating under a technology out-licensing model, Synaffix collaborates with multiple partners to advance therapeutic candidates across preclinical and clinical phases. The focus is centered on the healthcare sector, specifically biotechnology, with an emphasis on innovative cancer treatment solutions.
Who are the top competitors of Synaffix?
Synaffix's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Synaffix offer?
Synaffix offers GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads.
Who are Synaffix's investors?
Synaffix has 5 investors. Key investors include Lonza, BOM, BioGeneration Ventures, M-Ventures, and Aravis.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.